Gilead’s Hep C Drug Receives Approval In Japan - Analyst Reactions
March 31, 2015 at 11:58 AM EDT
Sovaldi becomes the first Gilead drug available in Japan. Overall analyst consensus is Strong Buy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.